Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 3-(4-(4-cyanophenyl)thiazol-2-yl)-2-(2,4-difluorophenyl)-1-(1h-1,2,4-triazol-1-yl)-2-butanol
2. Bms-207147
3. Er 30346
4. Er-30346
1. 182760-06-1
2. Er-30346
3. Bms-207147
4. Er 30346
5. Bms 207147
6. Ravuconazole [inn]
7. 95yh599jwv
8. 4-[2-[(2r,3r)-3-(2,4-difluorophenyl)-3-hydroxy-4-(1,2,4-triazol-1-yl)butan-2-yl]-1,3-thiazol-4-yl]benzonitrile
9. 194798-96-4
10. P-(2-((alphar,betar)-2,4-difluoro-beta-hydroxy-alpha-methyl-beta-(1h-1,2,4-triazol-1-ylmethyl)phenethyl)-4-thiazolyl)benzonitrile
11. Rcz
12. 4-(2-((2r,3r)-rel-3-(2,4-difluorophenyl)-3-hydroxy-4-(1h-1,2,4-triazol-1-yl)butan-2-yl)thiazol-4-yl)benzonitrile
13. 4-[2-[(1r,2r)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1,2,4-triazol-1-yl)propyl]thiazol-4-yl]benzonitrile
14. Benzonitrile, 4-[2-[(1r,2r)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1h-1,2,4-triazol-1-yl)propyl]-4-thiazolyl]-
15. Ravuconazol
16. Ravuconazolum
17. Unii-95yh599jwv
18. Benzonitrile, 4-(2-((1r,2r)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1h-1,2,4-triazol-1-yl)propyl)-4-thiazolyl)-
19. Ravuconazole (prop.inn)
20. Ravuconazole [mi]
21. Bms-207147/ravuconazole
22. Ravuconazole [mart.]
23. Ravuconazole [who-dd]
24. Schembl939026
25. Chembl294029
26. Dtxsid40171329
27. Chebi:143825
28. Zinc600547
29. Bcp05803
30. Ex-a3369
31. Bdbm50011476
32. Bms-20714
33. Mfcd00941002
34. Akos015962202
35. Bcp9000424
36. Cs-6927
37. Db06440
38. Bms-207,147
39. 3-(4-(4-cyanophenyl)thiazol-2-yl)-2-(2,4-difluorophenyl)-1-(1h-1,2,4-triazol-1-yl)-2-butanol
40. 4-[2-[(1r,2r)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1h-1,2,4-triazol-1-yl)propyl]-4-thiazolyl]benzonitrile
41. Hy-14272
42. D02556
43. A855884
44. Q7296826
45. Bms 207147;er 30346;bms207147;er30346;bms-207147;er-30346
46. (1r,2r)-4-[2-[2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-[1,2,4]triazol-1-yl-propyl]thiazol-4-yl]benzonitrile
47. (2r,3r)-3-[4-(4-cyanophenyl)thiazol-2-yl]-1-(1h-1,2,4-triazol-1-yl)-2-(2,4-difluorophenyl)-butan-2-ol
48. (2r,3r)-3-[4-(4-cyanophenyl)thiazol-2-yl]-2-(2,4-difluorophenyl)-1-(1h-1,2,4-triazol-1-yl)butan-2-ol
49. 4-(2-((2r,3r)-3-(2,4-difluorophenyl)-3-hydroxy-4-(1h-1,2,4-triazol-1-yl)butan-2-yl)thiazol-4-yl)benzonitrile
50. 4-[2-[(2r,3r)-3-(2,4-difluorophenyl)-3-hydroxy-4-(1,2,4-triazol-1-yl)b Utan-2-yl]-1,3-thiazol-4-yl]benzonitrile
51. Benzonitrile, 4-[2-[(1r,2r)-2-(2,4-difluro-phenyl)-2-hydroxy-1-methyl-3-(1h-1,2,4-triazol-1-yl)propyl]-4-thiazolyl]-
52. Benzonitrile, 4-[2-[2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1h-1,2,4-triazol-1-yl)propyl]-4-thiazolyl]-, [r-(r*,r*)]-
| Molecular Weight | 437.5 g/mol |
|---|---|
| Molecular Formula | C22H17F2N5OS |
| XLogP3 | 3.5 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 8 |
| Rotatable Bond Count | 6 |
| Exact Mass | 437.11218768 g/mol |
| Monoisotopic Mass | 437.11218768 g/mol |
| Topological Polar Surface Area | 116 Ų |
| Heavy Atom Count | 31 |
| Formal Charge | 0 |
| Complexity | 657 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 2 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Investigated for use/treatment in fungal infections, aspergillosis, candidiasis, and onychomycosis.
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
INTERMEDIATES SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
A Ravuconazole manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Ravuconazole, including repackagers and relabelers. The FDA regulates Ravuconazole manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Ravuconazole API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Ravuconazole manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Ravuconazole supplier is an individual or a company that provides Ravuconazole active pharmaceutical ingredient (API) or Ravuconazole finished formulations upon request. The Ravuconazole suppliers may include Ravuconazole API manufacturers, exporters, distributors and traders.
click here to find a list of Ravuconazole suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
Ravuconazole Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Ravuconazole GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Ravuconazole GMP manufacturer or Ravuconazole GMP API supplier for your needs.
A Ravuconazole CoA (Certificate of Analysis) is a formal document that attests to Ravuconazole's compliance with Ravuconazole specifications and serves as a tool for batch-level quality control.
Ravuconazole CoA mostly includes findings from lab analyses of a specific batch. For each Ravuconazole CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Ravuconazole may be tested according to a variety of international standards, such as European Pharmacopoeia (Ravuconazole EP), Ravuconazole JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Ravuconazole USP).
LOOKING FOR A SUPPLIER?
